OBJECTIVES

One in four persons in the US are currently infected with Human papillomavirus (HPV). The NIS-TEEN-2016 survey reported 65.9% 17-year-old adolescents completing the three dose regimen of HPV vaccination. The information on completion rates of HPV vaccination for older age groups is scarce. This study aimed to estimate the proportion of 9-26 year old completing the 2nd/3rd dose of HPV vaccine series between 2006-2016.

METHODS

A retrospective cohort study was conducted to assess the HPV vaccine dose completion in males and non-pregnant females aged 9-26 years. The Truven Health MarketScan Commercial Claims Database was used to identify at least one procedure code for HPV vaccine (CPT: 90649, 90651, 90650) during 2006-2016, with at least 13 months continuous enrollment prior-and-post to receipt of the first vaccine (index date). One-year and two-year completion rates were defined as proportion of persons receiving a dose within one and two years, respectively, of the minimum recommended schedule in the label for that dose. Results were stratified by gender and age-group.

RESULTS

The overall one-year 2nd and 3rd dose completion rate was 73.2% and 49.8%, respectively. One-year completion rate for 2nd dose was 75.6%, 74.6% and 67.1% for children 9-14 years, adolescents 15-18 years, and young adults 19-26 years, respectively. One-year 3rd dose completion rate was 51.4%, 51.5%, and 44.8% for children 9-14 years, adolescents 15-18 years, and young adults 19-26 years, respectively. One-year 2nd and 3rd dose completion rates were slightly higher for females, children and adolescents. Two-year 2nd and 3rd dose completion rates were 78.5% and 86%, respectively.

CONCLUSIONS

Vaccination completion rates in the study population were lower than those reported in NIS-TEEN survey. It is necessary to identify drivers of series completion to help decision-makers improve overall vaccine coverage.